Study results will be presented at the 2019 American Society of
Clinical Oncology (ASCO) Annual Meeting
DUARTE, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/CityofHope?src=hash" target="_blank"gt;#CityofHopelt;/agt;–A first-ever inhibitor of a cancer gene found in some lung, colorectal
and other cancers and the effectiveness of chimeric antigen receptor
(CAR) T cell therapy for patients with chronic lymphocytic leukemia are
just some of the research topics that City of Hope physicians and
scientists will present at the American Society of Clinical Oncology
(ASCO) 2019 annual meeting May 31 – June 4 in Chicago’s McCormick Place.
More than 38,000 oncology professionals and others will attend the
conference to learn about the latest scientific research on cancer
treatment, detection and prevention.
“ASCO brings together doctors, nurses and other medical professionals
with the important goal of discussing and sharing the latest cancer
research and treatment,” said Michael
Caligiuri, M.D., president of City of Hope National Medical Center
and Deana and Steve Campbell Physician-in-Chief Distinguished Chair.
“The annual meeting contributes to City of Hope’s deep commitment to
developing and implementing the most effective and innovative therapies.
City of Hope patients ultimately benefit from the knowledge shared at
City of Hope doctors and scientists will present oral and poster
presentations on a wide array of topics. They include:
First clinical trial testing KRAS G12C inhibitor in lung, colorectal
and other cancers
Abstract No: 3003
Monday, June 3, 8-11 a.m.
McCormick Place, S406
Fakih, M.D., professor of City of Hope’s Department of Medical
Oncology & Therapeutics Research and medical director of Judy
& Bernard Briskin Center for Clinical Research, will present a
study on the first in-human trial targeting the KRAS G12C oncogene (a
gene that when mutated drives tumor growth), which is found in up to 15%
of lung cancer patients and 3% of colorectal cancer patients. City of
Hope is one of the leading centers evaluating AMG 510, a targeted
therapy that, when taken orally on a daily basis, inhibits the growth of
KRAS G12C tumors.
The study examined the safety and efficacy of AMG 510 in 20 patients who
continue to take the therapy. Most of the patients had advanced cancer
and had taken three or more prior lines of treatment; the majority also
had colorectal cancer.
Initial results show that two patients with nonsmall cell lung cancer
(NSCLC) had partial remissions and six patients (two with NSCLC and four
with colorectal cancer) had cancer that had stop growing.
Results so far have demonstrated that the disease is safe for use in
patients and very well-tolerated with minimal side effects.
“This is the first-ever KRAS inhibitor that shows anti-tumor activity,”
Fakih said. “That is quite significant and depending on future results,
it has the potential to be life-changing for patients with KRAS G12C.”
Fakih will discuss updated clinical results during his ASCO presentation.
CAR T therapy for chronic lymphocytic lymphoma
Abstract No: 7501
CLL 004: Minimal residual disease (MRD) negative responses after
lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell
product, in patients (pts) with relapsed/refractory chronic lymphocytic
leukemia or small lymphocytic lymphoma (CLL/SLL).
Tuesday, June 4, 9:45 a.m. – 12:45 p.m.
McCormick Place, E451
Siddiqi, M.D., associate clinical professor of hematology and
director of the chronic lymphocytic lymphoma program within City of
Hope’s Toni Stephenson Lymphoma Center, will present an oral abstract on
a CAR T cell therapy for chronic lymphocytic leukemia (CLL).
Lisocabtagene maraleucel, also known as liso-cel and JCAR017, targets
CD19-positive cancer cells. There is not a lot of current data on CAR T
cell therapies for CLL, which is an incurable but slow, growing chronic
“At some point, CLL can become more aggressive and resistant to even the
new targeted therapies,” Siddiqi said. “Therefore, novel therapeutics
are needed, especially for patients with high risk disease (having
markers like deletion 17p, complex cytogenetics, unmutated IGVH) or
those who have not responded to other therapies.”
The phase 1 study had 15 evaluable patients who had all received prior
therapies, including ibrutinib (a multikinase inhibitor), and whose
cancer had returned. Initial data shows that there was no minimal
residual disease, or traces of cancer, in about 70% of patients as early
as 30 days after receiving the CAR T cells. Seven patients also achieved
complete remission. The overall response rate (patients who showed a
response to the therapy) at six months was 83%.
Patients also had manageable toxicities, or side effects caused by the
treatment; these included low grade cytokine release syndrome and
“Our study brings additional information showing that the product is
efficacious with manageable toxicities in patients who have progressed
after ibrutinib,” Siddiqi said.
Siddiqi will also present updated study results at the ASCO presentation.
In addition, City of Hope doctors will also speak at plenary and
education sessions. They include: Saro
Armenian, D.O., M.P.H., a City of Hope pediatric
hematologist/oncologist, will discuss pediatric
oncology abstracts on Sunday, June 2; Tanya
Dorff, M.D., associate clinical professor in City of Hope’s
Department of Medical Oncology & Therapeutics Research, will discuss prostate
cancer abstracts on Sunday, June 2, and will also speak at an education
session on diagnostics and therapeutics for prostate cancer on
Friday, May 31; Karen
Reckamp, M.D., M.S., co-director of City of Hope’s Lung Cancer and
Thoracic Oncology Program, will discuss lung
cancer abstracts on Monday, June 3; Alex
Herrera, M.D., assistant professor in City of Hope’s Department of
Hematology & Hematopoietic Cell Transplantation, will discuss relapsed
Hodgkin lymphoma at an education
session on Monday, June 3; Kim
Margolin, M.D., clinical professor in City of Hope’s Department of
Medical Oncology & Therapeutics Research, will discuss immunotherapy for
brain metastases at an education
session on Tuesday, June 4; and Jasmine
Zain, M.D., director of City of Hope’s T cell Lymphoma Program, will
lymphoma abstracts on Tuesday, June 4.
About City of Hope
City of Hope is an independent biomedical research and treatment center
for cancer, diabetes and other life-threatening diseases. Founded in
1913, City of Hope is a leader in bone
marrow transplantation and immunotherapy such as CAR
T cell therapy. City of Hope’s translational research and
personalized treatment protocols advance care throughout the world.
Human synthetic insulin and numerous
breakthrough cancer drugs are based on technology developed at the
institution. A National Cancer Institute-designated comprehensive cancer
center and a founding member of the National Comprehensive Cancer
Network, City of Hope is ranked one of America’s “Best Hospitals” in
cancer by U.S. News & World Report. Its main campus is
located near Los Angeles, with additional
locations throughout Southern California. For more information
about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.